TNM-based risk eligibility for adjuvant trials in renal cell carcinoma
Mené sur 1 545 patients atteints d'un carcinome rénal (durée médiane de suivi : 76 mois), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité de l'évérolimus en traitement adjuvant
Adjuvant therapy in renal cell carcinoma after surgery has been investigated in numerous clinical trials since the 1990s. However, only two trials have shown an improved disease-free survival that led to regulatory approval of pembrolizumab, on the basis of the results from the KEYNOTE-564 trial 1
by the US Food and Drug Administration (FDA) and the European Medicines Agency and sunitinib, on the basis of the results from the S-TRAC trial 2
by the US FDA.
The Lancet , commentaire, 2022